



Medicine Supply Notification

MSN/2025/007

Triptorelin acetate (Gonapeptyl[®] Depot) 3.75mg powder and solvent for suspension for injection pre-filled syringes

Tier 2 – medium impact*

Date of issue: 20/02/2025

Link: [Medicines Supply Tool](#)

Summary

- Triptorelin acetate (Gonapeptyl Depot[®]) 3.75mg powder and solvent for suspension for injection pre-filled syringes will be out of stock from early March 2025 until early January 2026.
- Alternative gonadotrophin-releasing hormone (GnRH) analogues remain available.

Actions Required

Clinicians should:

- not initiate new patients on triptorelin acetate (Gonapeptyl Depot[®]) 3.75mg powder and solvent for suspension for injection pre-filled syringes until the shortage has resolved;
- consider prescribing alternative gonadotrophin-releasing hormone (GnRH) analogues (see Supporting information below). Primary care prescribers may wish to consult specialist teams when considering an alternative GnRH. Individual summary of product characteristics (SmPCs) should be checked for indications, dosing, administration, contraindications, cautions and excipients as these vary. All prescribers should ensure that the patient:
 - is not intolerant to any of the excipients;
 - is counselled on the dose frequency of the new product;
 - receives appropriate training on the administration of the new product and is counselled on the appropriate dose and volume to administer if self-administering;
 - is signposted to online training videos if needed;
 - is provided with the appropriate ancillaries and a sharps bin for safe disposal of needles.
- if the above options are not considered appropriate, or primary care prescribers require specialist input, advice should be sought from specialists on management options.

Supporting information

Clinical Information

Triptorelin acetate (Gonapeptyl Depot[®]) 3.75mg powder and solvent for suspension for injection pre-filled syringes are licensed for:

- the treatment of hormone dependent locally advanced or metastatic prostate cancer (administered every 4 weeks);

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

- pre-operative reduction of myoma size to reduce the symptoms of bleeding and pain in women with symptomatic uterine myomas (administered every 4 weeks);
- symptomatic endometriosis confirmed by laparoscopy when suppression of the ovarian hormonogenesis is indicated to the extent that surgical therapy is not primarily indicated (administered every 4 weeks); and
- treatment of confirmed central precocious puberty [girls under 9 years, boys under 10 years] (dosing frequency can vary depending on response).

Table 1: Available parenteral GnRH analogues approved for indications covered by triptorelin acetate (Gonapeptyl Depot®) 3.75mg powder and solvent for suspension for injection pre-filled syringes

Agent	Brand	Presentation	Indication	Usual dose frequency
Goserelin	Zoladex® 3.6mg	Implant	Prostate cancer, endometriosis and uterine fibroids	28 days
	Zoladex® LA 10.8mg	Implant	Prostate cancer	12 weeks
Leuprorelin acetate	PROSTAP® PD DCS 1.88mg powder and solvent for prolonged-release suspension for injection	Pre-filled syringe	Precocious puberty	One month
	PROSTAP® SR DCS 3.75mg powder and solvent for prolonged-release suspension for injection	Pre-filled syringe	Prostate cancer, precocious puberty, endometriosis and uterine fibroids	One month
	PROSTAP® 3 DCS 11.25mg powder and solvent for prolonged-release suspension for injection	Pre-filled syringe	Prostate cancer, precocious puberty and endometriosis	Three months
	Staladex® 11.25mg	Implant	Prostate cancer	Three months
Triptorelin acetate	Decapeptyl® SR 3mg powder and solvent for suspension for injection	Powder and solvent	Prostate cancer, endometriosis and uterine fibroids	28 days
Triptorelin pamoate	Decapeptyl® SR 11.25mg powder and solvent for suspension for injection	Powder and solvent	Prostate cancer, precocious puberty and endometriosis	Three months
	Decapeptyl® SR 22.5mg powder and solvent for suspension for injection	Powder and solvent	Prostate cancer and precocious puberty	Six months

Individual SmPCs should be checked for indications, dosing and administration, contraindications, cautions and a full list of excipients as these vary.

Links to further information

[SmPC – Decapeptyl®](#)

[SmPC – Prostag®](#)

[BNF – Goserelin](#)

[BNF – Leuprorelin](#)

[SmPC – Staladex®](#)

[SmPC – Zoladex®](#)

[BNF – Triptorelin](#)



Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Specialist Pharmacy Service Regional Pharmacy Procurement Team, who will escalate to national teams if required.

REGION	Lead RPPS	Email	Associate RPPS	Email
Midlands	Andi Swain	andi.swain@nhs.net	Dav Manku	Dav.Manku@uhb.nhs.uk
East of England	James Kent	james.kent@nhs.net	Tracy McMillan	tracy.mcmillan2@nhs.net
London	Jackie Eastwood	j.eastwood@nhs.net	Daniel Johnson	Daniel.Johnson@nhs.net
North East and Yorkshire	David Allwood	davidallwood@nhs.net	Penny Daynes	penny.daynes@nhs.net
North West	Richard Bateman	richard.bateman@liverpoolft.nhs.uk	Andy Stewart	Andrew.stewart@liverpoolft.nhs.uk
South East	Alison Ashman	Alison.Ashman@berkshire.nhs.uk	Melanie Renney	melanie.renney@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk	Natalie Bryson	Natalie.Bryson@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2025/007.

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>